Background-Manual thrombus aspiration (TA) is effective to reduce the thrombus burden during primary percutaneous coronary intervention for ST-elevation myocardial infarction. The objective of this study is to assess the impact of manual TA on stent implantation during primary percutaneous coronary intervention. Methods and Results-Population of the EXAMINATION trial (n=1498) was divided into 2 groups according to the use of TA. Immediate angiographic results, primary patient-oriented end point (combination of all-cause death, myocardial infarction, and any revascularization) and secondary device-oriented end point (combination of cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularization), definite/probable stent thrombosis, and major/minor bleeding were evaluated at 2 years. A total of 976 (65.2%) patients were classified into TA group and 522 (34.8%) patients into nonthrombus aspiration group. Manual TA was most frequently used in patients with worse initial thrombolysis in myocardial infarction flow. The TA group received less number of stents implanted (1.35±0.62 versus 1.45±0.71, P=0.005) with bigger size (3.25±0.44 versus 3.11±0.46 mm, P<0.001) compared with the nonthrombus aspiration group. A higher rate of direct stenting (69.2% versus 43.3%, P<0.001) with lower rate of postdilatation (13.0% versus 18.0%, P<0.009) was also present in the TA group compared with the nonthrombus aspiration group. At 2-year follow-up, no differences in clinical end point were observed between groups. Conclusions-Manual TA during primary percutaneous coronary intervention is associated with a higher rate of direct stenting, a lower rate of postdilatation, and larger and less stents in comparison with conventional primary percutaneous coronary intervention. Conversely, manual TA had no apparent impact on clinical outcomes at long-term follow-up. Clinical Trial Registration-http://www.clinicaltrials.gov. Unique identifier: NCT00828087.
T hrombus embolization is detected up to 15% of ST-segment elevation myocardial infarction (STEMI) population and is likely responsible for suboptimal myocardial reperfusion, 1, 2 leading to an unfavorable clinical outcome. 3 Manual thrombus aspiration (TA) reduces thrombotic burden and receives a recommendation class IIa during the performance of primary percutaneous coronary intervention (PCI), 4 based on the results of the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS) trial, 5 later confirmed by several studies. [6] [7] [8] [9] However, the Thrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia (TASTE) trial, 10 recently published, showing no impact of manual TA on 30-day mortality, has reopened the debate about the role of this technique in STEMI patients.
There is scarcity of data about the impact between manual TA and stent complications as restenosis or stent thrombosis (ST). However, a recent study 11 reported that successful manual TA reduces restenosis in primary PCI involving bare metal stents (BMS).
Studies with first-generation drug-eluting stents in the setting of STEMI have showed controversial results, demonstrating reduction in the rate of repeat revascularization but increase in the rate of late ST. [12] [13] [14] [15] [16] [17] The post hoc analysis of Paclitaxel Eluting Stent Versus Conventional Stent in ST-segment Elevation Myocardial Infarction (PASSION) trial did not show reduction in major adverse cardiac events after TA in STEMI population treated with first-generation drugeluting stent in comparison with BMS. 15 The EXAMINATION trial 18 was the first study that evaluated the second-generation everolimus-eluting stent (EES) during primary PCI for STEMI, demonstrating reduction of target lesion revascularization (TLR), target vessel revascularization, and definite or probable ST in the EES group in comparison to the BMS group but no reduction in the combined end point of all-cause death, any recurrent myocardial infarction, and any revascularization at 1 year. 18 No data about possible interaction between TA and EES were reported.
We sought, therefore, to investigate the impact of TA on the immediate angiographic results and on the clinical outcome in STEMI population undergoing primary PCI enrolled in the EXAMINATION trial.
Methods
The EXAMINATION trial is a multicenter, multinational, prospective, controlled, superiority, all-comer trial that randomized (1:1) 1498 patients with STEMI up to 48 hours after the onset of symptoms requiring primary PCI, to receive a second-generation EES (Xience V; Abbott Vascular, Santa Clara, CA) or a BMS (Multilink Vision; Abbott Vascular, Santa Clara, CA). The rationale of the EXAMINATION trial has been previously published. 19 Exclusion criteria were lesions requiring stent sizes <2.25 or >4 mm; STEMI caused by ST; age <18 years; pregnancy; known intolerance to aspirin, clopidogrel, heparin, cobalt-chromium, or other components of the stents; and chronic treatment with antivitamin K agents.
Primary PCI was performed according to the standard medical practices in each center. The protocol allowed the use of manual TA, unfractionated heparin, and bivalirudin or glycoprotein IIb/IIIa inhibitors according to the operator criteria. A loading dose of aspirin (≥250 mg) and clopidogrel (≥300 mg) was prescribed before primary PCI. Aspirin (≥100 mg/d) was prescribed indefinitely and clopidogrel (75 mg/d) for at least 1 year after primary PCI. No mechanical thrombectomy was performed.
The study was conducted according to the Declaration of Helsinki and applicable local requirements. All patients gave written informed consent. Each participating center submitted and received the approval of their Medical Ethics Committee for the informed consent and for the protocol. The Institutional Review Board approval was obtained.
For the purpose of this substudy, patients enrolled in the EXAMINATION trial were divided into 2 groups according to the use of manual TA (TA group versus nonthrombus aspiration [NTA] group).
Clinical End Points
For the purpose of this analysis, all the end points were evaluated at 2 years. 20 The primary end point of the study was the patient-oriented combined end point of all-cause death, any myocardial infarction (MI), and any revascularization. 19 The secondary end point of the study included the stent-oriented combined end point of cardiac death, target vessel MI, and clinically driven TLR. 19 The other secondary end points also examined were all-cause and cardiac death; recurrent MI (World Health Organization extended definition) 21 and target vessel MI; any revascularization, clinically driven TLR; definite or probable ST; and major and minor bleeding. 19 Optimization of stent implantation was evaluated by the number of implanted stents, the rate of direct stenting and postdilatation, the maximal diameter of the implanted stents, the total stented length segment, the final thrombolysis in myocardial infarction (TIMI) flow, and the resolution of the ST-segment elevation after primary PCI.
All clinical events were adjudicated by an independent Clinical Event Committee (Cardialysis, Rotterdam, The Netherlands) according to hierarchical principle. All the end points were analyzed according to the use of manual TA devices (TA versus NTA group) and within TA and NTA groups according to the use of EES or BMS.
Statistical Analysis
Continuous variables were explored for normal distribution with the Kolmogorov-Smirnov test. Normally distributed variables were expressed as mean (1 standard deviation) and non-normally distributed variables were expressed as median (interquartile range) and were compared using Student t or with Mann-Whitney tests as appropriate. Categorical variables were expressed as count (percentage) and were compared using the χ 2 test. To exclude confounding in primary end point, a multivariate analysis using a Cox regression model was performed. The following variables were included in the model: manual TA, center where the PCI was performed, age, sex, diabetes mellitus, previous MI, previous coronary artery by-pass grafting, type of PCI, Killip class on admission, initial TIMI flow, use of IIb/IIIa inhibitors, direct stenting, postdilatation, maximum stent diameter, total stented length, and number of implanted stents. Time-to-event analysis was assessed with the Kaplan-Meier method, with differences between groups compared with the log-rank test. Furthermore, a test for interaction by manual TA was performed to evaluate the interaction between manual TA and EES or BMS. The results were reported as hazard ratio together with the 95% confidence interval. All P values were 2 tailed, with statistical significance set at a level of <0.05. Statistical analyses were performed using SPSS Statistics 20.0 (SPSS Inc., Chicago, IL).
WHAT IS KNOWN
• Thrombus embolization during ST-segment elevation myocardial infarction is related to poor clinical outcomes. Manual thromboaspiration reduces thrombus burden.
• Benefits of thrombus aspiration have not been demonstrated consistently in prior clinical trials.
WHAT THE STUDY ADDS
• Our study evaluates the outcomes of manual thrombus aspiration during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
• Manual thrombus aspiration is associated with higher rate of direct stenting and lower rate of postdilatation, larger and fewer stents when compared with no thrombus aspiration.
• Manual thrombus aspiration did not have an impact on long-term outcome.
Results

Clinical Characteristics
The 1498 patients enrolled in the EXAMINATION trial were divided into TA (n=976, 65.2%) and NTA groups (n=522, 34.8%). Patients in the TA group were younger (60.57±12.17 versus 62.37±12.71, P=0.007) and showed lower rates of female sex ( 
Angiographic and Procedural Characteristics
The TA group showed higher use of IIb/IIIa inhibitors (59.0% versus 40.0%, P<0.001), higher rate of direct stenting (69.2% versus 43.3%, P<0.001), and lower rate of postdilatation (13.0% versus 18.0%, P<0.009). Less and larger stents were used in the TA group compared with the NTA group (number of stents: 1.35±0.62 versus 1.45±0.71, P=0.005; maximal stent diameter: 3.25±0.44 versus 3.11±0.46 mm, P<0.001). On average, the initial TIMI flow was lower in the TA group compared with the NTA group (0.58±1.04 versus 1.62±1.28, P<0.001), without any difference in the final TIMI flow (2.90±0.44 versus 2.88±0.51, P=0.549; Table 2 ).
Long-Term Clinical Outcomes
Two-year clinical follow-up did not show any difference in the primary end point between TA and NTA groups ( The test for interaction by manual TA showed that patients in the TA group receiving EES had less TLR than those who received BMS (2.2% versus 5.2%, P=0.049).
A Kaplan-Meier curve for clinically driven TLR is presented in the Figure ( See Tables I, II , and III in the Data Supplement).
Discussion
The present analysis shows that (1) manual TA seems to optimize the immediate angiographic result with the implantation of less and larger stents and (2) manual TA did not have an impact on long-term outcome.
Optimization in Angiographic Results and Stent Implantation
Although randomized trials have demonstrated that manual TA improves angiographic and clinical outcomes, in clinical practice, such devices are most often used in those patients presenting with high thrombotic burden. Our study confirms this finding as this device was more frequently used in larger MI with poorer clinical condition (higher Killip class and higher myocardial necrosis biomarkers peak). Moreover, a higher rate of IIb/IIIa use was noted in those patients to reduce the thrombotic burden. Use of manual TA allows operators to achieve an angiographic success equal to those patients in whom manual TA was not used in terms of final TIMI flow. Our findings are in line with those of the Korea Acute Myocardial Infarction Registry, 22 where TA was more used in patients with larger STEMI (higher peak elevation of cardiac necrosis enzymes), worse STEMI presentation (more prevalence of STEMI Killip class>I on admission), and more thrombotic burden (higher rate of low initial TIMI flow) in comparison with NTA patients. However, the TA and NTA groups showed the same rates of final TIMI flow and ST resolution (>50%; 83.8% versus 81.8%, P=0.331).
In addition to the potential benefit in reperfusion, our study showed that TA optimized PCI. TA reduced the rates of predilatation 23, 24 and postdilatation, 25, 26 which are usually associated with no-reflow phenomenon and poor prognosis after a STEMI. Manual TA also allowed implantation of bigger and fewer stents. The majority of the studies have failed to demonstrate differences in stents diameter and the number of implanted. 6, 8, 15, 22, 27, 28 In contrast, Bulum et al 11 demonstrated a larger stent diameter after manual TA, in patients treated with BMS in STEMI. Recently, the TASTE trial showed the need for fewer stents per procedure in the manual TA group in comparison with conventional PCI. 10 It is noteworthy that in our study, only manual TA was used. Previous studies have demonstrated the superiority in angiographic results of manual TA over mechanical thrombectomy. 29, 30 The post hoc analysis of the impact of thrombectomy in the PASSION trial 15 failed to show any value of thrombectomy on the number and size of implanted stents; in that trial, however, both manual and mechanical thrombectomy were used and this fact could have influenced those results.
Few publications about the costs of different types of thrombectomy devices in the setting of STEMI are reported, 31, 32 and only one head-to-head comparison between thrombectomy prior to primary PCI and conventional primary PCI has been described. 33 The Rescue Percutaneous Thrombectomy system (Boston Scientific, Maple Grove, MN), removing the coronary thrombus by a vacuum pump system in a similar way to manual TA, was used in that trial. There were no differences between the 2 groups, regarding the initial procedure cost and the total cost during hospitalization despite the need for more stents in the thrombectomy group. We can hypothesize that the observed reduction in the number of implanted stents and the lower number of angioplasty balloons for predilatation and postdilatation may reduce costs in primary PCI. Therefore, further studies about the cost-effectiveness implications of the use of manual TA in primary PCI are warranted.
Long-Term Clinical Outcomes
Patients in the TA group were younger, with less presence of previous MI and multivessel disease but presented larger STEMI with more severe presentation than patients in the NTA group. These differences in baseline characteristics, as well as the use of the optimal medical therapy and the reduction in time delays, may cause a lack of difference in long-term clinical results, despite the optimization of the angiographic and stent characteristics by manual TA. Nevertheless, after adjustment for important covariates including age, sex, comorbidities, and angiographic characteristics, no differences in the primary end point were found.
These clinical results are not compatible with TAPAS trial, 5 the only randomized clinical trial evaluating manual TA during primary PCI with long-term follow-up, but are similar to the results of the largest real-world registry 22 and to the analysis of the interaction between TA and first-generation drug-eluting stent (Paclitaxel) in the PASSION trial. 15 Furthermore, these data are consistent with the TASTE trial, 10 even though the primary end point (all-cause mortality at 30 days) was evaluated at short term in this randomized clinical trial.
In the EXAMINATION 18 and the COMFORTABLE AMI 34 trials, manual TA was performed ≈2/3 of the patients. However, in studies involving first-generation drug-eluting stent, the use of manual TA was not widespread and was only performed in a small proportion of the patients. Manual TA reduces the amount of thrombotic material between the vascular wall and the stent, allowing a closer contact between the vessel wall and the antiproliferative drug, which could inhibit endothelial proliferation in a more potent way. 35, 36 It is interesting to note that our trial found an association between the use of manual TA and clinical outcomes (TLR) favoring EES compared with BMS. 18 Furthermore, these data are in line with that of the COMFORTABLE AMI trial. 34 In that study, major adverse cardiac event and TLR rates within TA group were associated with better outcomes (hazard ratio [95% confidence interval]; major adverse cardiac event: 0.40 [0.21-0.76], P=0.005; TLR: 0.28 [0.13-0.59], P<0.001), with the use of biolimus-eluting stents except in patients not treated with TA.
Study Limitations
First, this study is a retrospective, nonrandomized, subgroup analysis of the EXAMINATION trial, which failed to show any difference in terms of primary end point between EES and BMS. Differences in baseline clinical, angiographic characteristics and STEMI presentation may have introduced confounding factors and bias into the analysis. Second, baseline angiographic data were not available and therefore could not be included in the multivariate analysis. In spite of this limitation, this is the study with the largest number of patients included, related with optimization on stent implantation by manual TA during primary PCI. Third, myocardial reperfusion was only assessed by TIMI flow and ST-segment resolution, and no other parameters, such as the evaluation by nuclear magnetic resonance or the tissue myocardial perfusion grade, were performed. Fourth, our substudy was not powered to detect differences in TLR. For this reason, the lack of difference in terms of TLR between EES and BMS within the NTA group may be a play of chance related to the sample size. Thus, other studies are needed to confirm this observation.
Conclusions
Manual TA during primary PCI is associated with a higher rate of direct stenting, a lower rate of postdilatation, and larger and less stents in comparison with conventional primary PCI. However, it seems to have no impact on long-term clinical outcome. 
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Figure.
Kaplan-Meier curve for clinically driven target lesion revascularization. BMS indicates bare metal stent; EES, everolimus-eluting stent; NTA, nonthrombus aspiration; TA, thrombus aspiration; and TLR, target lesion revascularization.
